UTRF Licensee Announces Positive Phase 2 Clinical Results of VERU-111 for COVID-19

UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day… Read More

UTHSC Researchers Play Role in Supporting Development of COVID-19 Vaccines

To reduce the risk to workers developing and testing the COVID-19 vaccine, Pfizer-BioNTech and other companies have utilized a surrogate system, one of which was developed in the laboratory of Michael Whitt, PhD, a UTHSC virologist and UTRF innovator. Story written by Peggy Reisser, UTHSC  Researchers at the University of Tennessee Health Science Center have… Read More

Discover 2020: UTRF Annual Report

UTRF is delighted to share Discover 2020, which celebrates our innovators and UTRF’s impact on innovation, new venture formation, and corporate engagement for the University of Tennessee. Download accessible PDF.   View past annual reports.  … Read More